#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	16152	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2661	738.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1692	1692	C	974	C	974	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	16152	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2661	738.9	0	HET	.	.	.	C1121A,T	.	1121	1121	C	1629	1629	C	1022	C,A,T	826,194,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	16152	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2661	738.9	0	HET	.	.	.	C611T,G,A	.	611	611	C	1119	1119	C	1008	C,T,G,A	769,234,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26300	23S	2890	2890	99.86	23S.l6.c30.ctg.1	4151	790.2	0	.	n	.	0	T695C	SNP	695	695	T	1333	1333	C	1002	C,T,A	996,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26300	23S	2890	2890	99.86	23S.l6.c30.ctg.1	4151	790.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1975	1975	A	1089	A,C	1088,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26300	23S	2890	2890	99.86	23S.l6.c30.ctg.1	4151	790.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2609	2609	C	849	C,T	846,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26300	23S	2890	2890	99.86	23S.l6.c30.ctg.1	4151	790.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3235	3235	T	901	T,C,G	897,3,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26300	23S	2890	2890	99.86	23S.l6.c30.ctg.1	4151	790.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2683	2683	A	749	A,C	748,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2292	folP	852	852	100.0	folP.l6.c4.ctg.1	1995	143.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1201	1203	AGC	229;231;231	A,T;G,C,T;C	228,1;229,1,1;231	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5764	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3965	181.3	1	SNP	p	S91F	0	.	.	271	273	TCC	888	890	TCC	222;222;223	T;C;C	222;222;223	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5764	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3965	181.3	1	SNP	p	D95G	0	.	.	283	285	GAC	900	902	GAC	230;232;232	G,C,T;A,C,G;C	228,1,1;229,2,1;232	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5764	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3965	181.3	1	SNP	p	D95N	0	.	.	283	285	GAC	900	902	GAC	230;232;232	G,C,T;A,C,G;C	228,1,1;229,2,1;232	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	1996	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1768	140.5	1	SNP	p	G45D	1	.	.	133	135	GAC	663	665	GAC	216;214;217	G;A;C	216;214;217	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1210	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1487	101.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5398	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3538	190.2	1	SNP	p	D86N	0	.	.	256	258	GAC	861	863	GAC	232;228;227	G,T;A;C,A	231,1;228;226,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5398	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3538	190.2	1	SNP	p	S87I	0	.	.	259	261	AGT	864	866	AGT	223;224;225	A,G;G;T,C	221,2;224;224,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5398	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3538	190.2	1	SNP	p	S87W	0	.	.	259	261	AGT	864	866	AGT	223;224;225	A,G;G;T,C	221,2;224;224,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5398	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3538	190.2	1	SNP	p	S87R	0	.	.	259	261	AGT	864	866	AGT	223;224;225	A,G;G;T,C	221,2;224;224,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5398	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3538	190.2	1	SNP	p	S88P	0	.	.	262	264	TCC	867	869	TCC	224;223;225	T;C,A;C	224;222,1;225	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4536	parE	1986	1986	100.0	parE.l15.c17.ctg.1	3064	184.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1714	1716	GGC	245;243;239	G;G,T;C,T	245;242,1;238,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4500	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2883	194.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1483	1485	GCA	256;254;253	G;C;A	256;254;253	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4500	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2883	194.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1486	1488	ATC	253;251;253	A;T;C,A	253;251;252,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4500	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2883	194.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1498	1500	GTG	247;246;248	G;T,G;G,T	247;245,1;246,2	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4500	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2883	194.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1498	1500	GTG	247;246;248	G;T,G;G,T	247;245,1;246,2	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4500	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2883	194.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2002	2004	ACC	242;240;241	A;C,A;C	242;238,2;241	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4500	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2883	194.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2056	2058	GCG	228;227;229	G,T;C;G	227,1;227;229	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4500	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2883	194.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2056	2058	GCG	228;227;229	G,T;C;G	227,1;227;229	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4500	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2883	194.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2179	2181	GGC	246;249;246	G,T;G;C,A	244,2;249;245,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4500	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2883	194.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2188	2190	GGC	245;243;243	G,T,C;G;C,T	242,2,1;243;241,2	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4500	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2883	194.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2206	2208	CCG	230;234;237	C;C;G,T	230;234;236,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6064	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3743	202.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2546	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2286	138.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	802	802	C	218	C,A	217,1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	270	porB1a	984	205	94.15	porB1a.l15.c30.ctg.1	244	32.8	0	.	p	.	0	S271T	NONSYN	811	813	TCG	131	133	ACT	62;62;62	A;C;T	62;62;62	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	270	porB1a	984	205	94.15	porB1a.l15.c30.ctg.1	244	32.8	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	137	139	GAT	62;62;62	G;A;T	62;62;62	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	270	porB1a	984	205	94.15	porB1a.l15.c30.ctg.1	244	32.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	140	142	AGT	62;61;61	A;G;T	62;61;61	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	270	porB1a	984	205	94.15	porB1a.l15.c30.ctg.1	244	32.8	0	.	p	.	0	N277H	NONSYN	829	831	AAC	149	151	CAC	61;61;61	C;A;C	61;61;61	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	G38E	NONSYN	112	114	GGA	571	573	GAA	262;261;267	G,T,A;A;A,C	260,1,1;261;266,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	S46G	NONSYN	136	138	AGC	595	597	GGC	259;258;256	G;G,A,C;C,A	259;256,1,1;255,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	E48G	NONSYN	142	144	GAA	601	603	GGA	262;257;260	G;G;A,G,C	261;256;257,1,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	T87A	NONSYN	259	261	ACT	718	720	GCT	230;229;228	G;C;T	230;229;228	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	T89S	NONSYN	265	267	ACC	724	726	AGC	223;222;221	A;G;C	223;222;221	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	.	MULTIPLE	358	359	AA	816	817	CG	225;226	C;G	225;226	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	.	MULTIPLE	361	362	GA	819	821	CAG	228;231;235	C;A;G	228;231;235	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	N122K	NONSYN	364	366	AAC	823	825	AAA	233;232;232	A,C;A;A	232,1;232;232	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	K143E	NONSYN	427	429	AAA	886	888	GAA	257;257;256	G;A;A	257;257;256	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	V151A	NONSYN	451	453	GTA	910	912	GCA	251;248;251	G;C;A,G	251;248;250,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1102	1104	ACT	220;220;222	A,T;C,T;T,G,A	218,2;219,1;220,1,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1111	1113	ATG	223;223;224	A;T;G,A	223;223;223,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1225	1227	GCA	222;220;221	G;C,A;A	222;219,1;221	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1228	1230	ACG	221;219;218	A;C;G,C	221;219;217,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	S258G	NONSYN	772	774	AGT	1231	1233	GGG	218;217;218	G;G;G,T	218;217;217,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1234	1236	GTT	215;215;213	G,T;T;T	214,1;215;213	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1294	1296	GTA	240;240;240	G;T,C,A;A	240;238,1,1;240	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1333	1335	ACT	244;244;244	A,C;C;T	243,1;244;244	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1339	1341	GAT	250;251;248	G;A,T;T	250;250,1;248	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1351	1353	CAC	259;258;260	C;A;C,T	259;258;259,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	1	SNP	p	G120K	1	.	.	358	360	AAG	816	818	CGG	225;226;227	C;G;G	225;226;227	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	1	SNP	p	A121D	1	.	.	361	363	GAC	819	822	CGC	228;235;231	C;G;C,T	228;235;230,1	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2874	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1654	211.9	1	SNP	p	D121N	0	.	.	361	363	GAC	819	822	CGC	228;235;231	C;G;C,T	228;235;230,1	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9900	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	5344	230.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2280	2282	AAT	230;232;230	A,G;A,C;T,G,C	229,1;231,1;227,2,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1344	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1498	112.1	1	SNP	p	V57M	1	.	.	169	171	ATG	785	787	ATG	223;223;220	A;T;G,T	223;223;219,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
